China Resources Pharmaceutical Group Limited (3320.HK)
HKD 5.46
(-0.18%)
HKD 5.46
(-0.18%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 43.36 Billion HKD | 8.25% |
| 2022 | 39.13 Billion HKD | 10.61% |
| 2021 | 35.38 Billion HKD | 9.56% |
| 2020 | 32.29 Billion HKD | -5.07% |
| 2019 | 34.01 Billion HKD | -2.61% |
| 2018 | 34.93 Billion HKD | 23.53% |
| 2017 | 28.27 Billion HKD | 17.28% |
| 2016 | 24.1 Billion HKD | 3.92% |
| 2015 | 23.19 Billion HKD | 7.95% |
| 2014 | 21.49 Billion HKD | 6.66% |
| 2013 | 20.14 Billion HKD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 22.68 Billion HKD | 0.0% |
| 2023 Q4 | 19.86 Billion HKD | 0.0% |
| 2023 FY | 42.36 Billion HKD | 8.25% |
| 2023 Q2 | 22.34 Billion HKD | 0.0% |
| 2022 Q2 | 19.83 Billion HKD | 0.0% |
| 2022 FY | 39.13 Billion HKD | 10.61% |
| 2022 Q4 | 19.3 Billion HKD | 0.0% |
| 2021 Q2 | 17.46 Billion HKD | 0.0% |
| 2021 Q4 | 17.91 Billion HKD | 0.0% |
| 2021 FY | 35.38 Billion HKD | 9.56% |
| 2020 FY | 32.29 Billion HKD | -5.07% |
| 2020 Q4 | 17.42 Billion HKD | 0.0% |
| 2020 Q2 | 14.86 Billion HKD | 0.0% |
| 2019 Q2 | 17.43 Billion HKD | 0.0% |
| 2019 FY | 34.01 Billion HKD | -2.61% |
| 2019 Q4 | 16.58 Billion HKD | 0.0% |
| 2018 FY | 34.93 Billion HKD | 23.53% |
| 2018 Q2 | 16.88 Billion HKD | 0.0% |
| 2018 Q4 | 18.04 Billion HKD | 0.0% |
| 2017 FY | 28.27 Billion HKD | 17.28% |
| 2017 Q2 | 12.52 Billion HKD | 0.0% |
| 2017 Q4 | 15.74 Billion HKD | 0.0% |
| 2016 FY | 24.1 Billion HKD | 3.92% |
| 2016 Q4 | 12.35 Billion HKD | 0.0% |
| 2016 Q2 | 11.75 Billion HKD | 0.0% |
| 2015 Q2 | 11.45 Billion HKD | 0.0% |
| 2015 FY | 23.19 Billion HKD | 7.95% |
| 2015 Q4 | 11.74 Billion HKD | 0.0% |
| 2014 Q4 | 5.79 Billion HKD | 7.95% |
| 2014 Q3 | 5.37 Billion HKD | 0.0% |
| 2014 Q2 | 5.37 Billion HKD | 0.0% |
| 2014 Q1 | 5.37 Billion HKD | 0.0% |
| 2014 FY | 21.49 Billion HKD | 6.66% |
| 2013 Q3 | 5.03 Billion HKD | 0.0% |
| 2013 FY | 20.14 Billion HKD | 0.0% |
| 2013 Q2 | 5.03 Billion HKD | 0.0% |
| 2013 Q1 | 5.03 Billion HKD | 0.0% |
| 2013 Q4 | 5.37 Billion HKD | 6.66% |
| 2012 Q4 | 5.03 Billion HKD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 167.43 Million HKD | -25800.256% |
| Grand Pharmaceutical Group Limited | 6.52 Billion HKD | -564.714% |
| Extrawell Pharmaceutical Holdings Limited | 28.77 Million HKD | -150587.488% |
| Wai Yuen Tong Medicine Holdings Limited | 394.81 Million HKD | -10884.023% |
| Qianhai Health Holdings Limited | -35.6 Million HKD | 121905.332% |
| Lee's Pharmaceutical Holdings Limited | 551.31 Million HKD | -7766.042% |
| Essex Bio-Technology Limited | 1.53 Billion HKD | -2717.29% |
| Tongfang Kontafarma Holdings Limited | 471.29 Million HKD | -9101.589% |
| PuraPharm Corporation Limited | 216.62 Million HKD | -19918.72% |
| SSY Group Limited | 3.48 Billion HKD | -1142.881% |
| JBM (Healthcare) Limited | 319.41 Million HKD | -13476.763% |
| Jacobson Pharma Corporation Limited | 620.47 Million HKD | -6889.218% |